Format

Send to

Choose Destination
Chest. 2008 Dec;134(6):1287-1298. doi: 10.1378/chest.08-0364.

Changing global epidemiology of pulmonary manifestations of HIV/AIDS.

Author information

1
Canadian HIV Trials Network, University of British Columbia, Vancouver, BC, Canada.
2
Division of Infectious Diseases, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
3
Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: 8527jmontaner@cfenet.ubc.ca.

Abstract

Tremendous advances have occurred in the care of patients with HIV/AIDS resulting from the advent of highly active antiretroviral therapy (HAART). This has led to differences in the presentations of HIV-related pulmonary disease. Infections such as bacterial pneumonias, particularly Streptococcus pneumoniae, remain commonplace, while opportunistic agents such as Pneumocystis jirovecii remain a concern in patients without adequate access to optimal medical care. The tuberculosis epidemic, once thought to be slowing, has been re-energized by the spread of HIV, particularly in sub-Saharan Africa. Unusual inflammatory responses due to a phenomenon of immune reconstitution, are now recognized as a consequence of HAART, with a reported incidence of IRIS in this setting ranges from 7 to 45% in retrospective reviews. Noninfectious pulmonary conditions such as chronic obstructive lung disease and pulmonary malignancies are gaining prominence as patients are accessing antiretroviral care and enjoying significantly extended survival.

PMID:
19059959
DOI:
10.1378/chest.08-0364
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center